A novel molecular classification method for osteosarcoma based on tumor cell differentiation trajectories

Abstract

Subclassification of tumors based on molecular features may facilitate therapeutic choice and increase the response rate of cancer patients. However, the highly complex cell origin involved in osteosarcoma (OS) limits the utility of traditional bulk RNA sequencing for OS subclassification. Single-cell RNA sequencing (scRNA-seq) holds great promise for identifying cell heterogeneity. However, this technique has rarely been used in the study of tumor subclassification. By analyzing scRNA-seq data for six conventional OS and nine cancellous bone (CB) samples, we identified 29 clusters in OS and CB samples and discovered three differentiation trajectories from the cancer stem cell (CSC)-like subset, which allowed us to classify OS samples into three groups. The classification model was further examined using the TARGET dataset. Each subgroup of OS had different prognoses and possible drug sensitivities, and OS cells in the three differentiation branches showed distinct interactions with other clusters in the OS microenvironment. In addition, we verified the classification model through IHC staining in 138 OS samples, revealing a worse prognosis for Group B patients. Furthermore, we describe the novel transcriptional program of CSCs and highlight the activation of EZH2 in CSCs of OS. These findings provide a novel subclassification method based on scRNA-seq and shed new light on the molecular features of CSCs in OS and may serve as valuable references for precision treatment for and therapeutic development in OS.

References

[1] Prudowsky, Z. D. & Yustein, J. T. Recent insights into therapy resistance in osteosarcoma. Cancers 13, 83 (2020).

[2] Benjamin RS. Adjuvant and neoadjuvant chemotherapy for osteosarcoma: a historical perspective. Adv. Exp. Med. Biol., 2020, 1257: 1-10

[3] Jafari F et al. Osteosarcoma: a comprehensive review of management and treatment strategies. Ann. Diagn. Pathol., 2020, 49: 151654

[4] Xie L et al. Apatinib for advanced osteosarcoma after failure of standard multimodal therapy: an open label phase II clinical trial. Oncologist, 2019, 24: e542-e550

[5] Grignani G et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol., 2015, 16: 98-107

[6] Davis LE et al. Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma. J. Clin. Oncol., 2019, 37: 1424-1431

[7] Kallen ME, Hornick JL. The 2020 WHO classification: what’s new in soft tissue tumor pathology? Am. J. Surg. Pathol., 2021, 45: e1-e23

[8] Jiang YZ et al. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. Cell Res., 2021, 31: 178-186

[9] Scott MC et al. Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach. Bone, 2011, 49: 356-367

[10] Mutsaers AJ, Walkley CR. Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells? Bone, 2014, 62: 56-63

[11] Montanini L et al. MicroRNA cloning and sequencing in osteosarcoma cell lines: differential role of miR-93. Cell Oncol., 2012, 35: 29-41

[12] Le Nail, L. R. et al. Comparison of tumor- and bone marrow-derived mesenchymal stromal/stem cells from patients with high-grade osteosarcoma. Int. J. Mol. Sci. 19, 707 (2018).

[13] Lytle NK, Barber AG, Reya T. Stem cell fate in cancer growth, progression and therapy resistance. Nat. Rev. Cancer, 2018, 18: 669-680

[14] Rycaj K, Tang DG. Cell-of-origin of cancer versus cancer stem cells: assays and interpretations. Cancer Res., 2015, 75: 4003-4011

[15] Mizushima E et al. Osteosarcoma-initiating cells show high aerobic glycolysis and attenuation of oxidative phosphorylation mediated by LIN28B. Cancer Sci., 2020, 111: 36-46

[16] Zhou Z et al. The CD24(+) cell subset promotes invasion and metastasis in human osteosarcoma. EBioMedicine, 2020, 51: 102598

[17] Brown HK, Tellez-Gabriel M, Heymann D. Cancer stem cells in osteosarcoma. Cancer Lett., 2017, 386: 189-195

[18] Peng J et al. Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. Cell Res., 2019, 29: 725-738

[19] Dong R et al. Single-cell characterization of malignant phenotypes and developmental trajectories of adrenal neuroblastoma. Cancer Cell, 2020, 38: 716-733 e716

[20] Zhou Y et al. Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma. Nat. Commun., 2020, 11

[21] Abarrategi A et al. Osteosarcoma: cells-of-origin, cancer stem cells, and targeted therapies. Stem Cells Int., 2016, 2016: 3631764

[22] Han Y et al. Lkb1 deletion in periosteal mesenchymal progenitors induces osteogenic tumors through mTORC1 activation. J. Clin. Invest., 2019, 129: 1895-1909

[23] Marom R, Rabenhorst BM, Morello R. Osteogenesis imperfecta: an update on clinical features and therapies. Eur. J. Endocrinol., 2020, 183: R95-R106

[24] Wilson A et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell, 2008, 135: 1118-1129

[25] Eich ML, Athar M, Ferguson JE 3rd, Varambally S. EZH2-targeted therapies in cancer: hype or a reality. Cancer Res., 2020, 80: 5449-5458

[26] Fang C et al. Cancer-specific CTCF binding facilitates oncogenic transcriptional dysregulation. Genome Biol., 2020, 21

[27] Liu, Y. C., Yeh, C. T. & Lin, K. H. Cancer stem cell functions in hepatocellular carcinoma and comprehensive therapeutic strategies. Cells 9, 1331 (2020).

[28] Jin K et al. HOXB7 is an ERalpha cofactor in the activation of HER2 and multiple ER target genes leading to endocrine resistance. Cancer Discov., 2015, 5: 944-959

[29] Jing D et al. Lymphocyte-specific chromatin accessibility pre-determines glucocorticoid resistance in acute lymphoblastic leukemia. Cancer Cell, 2018, 34: 906-921 e908

[30] Karam N et al. Bone-specific overexpression of PITX1 induces senile osteoporosis in mice through deficient self-renewal of mesenchymal progenitors and Wnt pathway inhibition. Sci. Rep., 2019, 9

[31] Sen B et al. Beta-catenin preserves the stem state of murine bone marrow stromal cells through activation of EZH2. J. Bone Min. Res., 2020, 35: 1149-1162

[32] Sun S et al. EZH2/H3K27Me3 and phosphorylated EZH2 predict chemotherapy response and prognosis in ovarian cancer. PeerJ, 2020, 8: e9052

[33] Navet, B. et al. The intrinsic and extrinsic implications of RANKL/RANK signaling in osteosarcoma: from tumor initiation to lung metastases. Cancers 10, 398 (2018).

[34] Heymann MF, Lezot F, Heymann D. The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma. Cell Immunol., 2019, 343: 103711

[35] Endo-Munoz L, Evdokiou A, Saunders NA. The role of osteoclasts and tumour-associated macrophages in osteosarcoma metastasis. Biochim. Biophys. Acta, 2012, 1826: 434-442

[36] Dhupkar P, Gordon N, Stewart J, Kleinerman ES. Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases. Cancer Med., 2018, 7: 2654-2664

[37] Lilienthal, I. & Herold, N. Targeting molecular mechanisms underlying treatment efficacy and resistance in osteosarcoma: a review of current and future strategies. Int. J. Mol. Sci. 21, 6885 (2020).

[38] Omer N et al. Phase-II trials in osteosarcoma recurrences: a systematic review of past experience. Eur. J. Cancer, 2017, 75: 98-108

[39] Zhao J, Dean DC, Hornicek FJ, Yu X, Duan Z. Emerging next-generation sequencing-based discoveries for targeted osteosarcoma therapy. Cancer Lett., 2020, 474: 158-167

[40] S NK et al. Morphological classification of pancreatic ductal adenocarcinoma that predicts molecular subtypes and correlates with clinical outcome. Gut, 2020, 69: 317-328

[41] Wang W et al. Molecular subtyping of colorectal cancer: recent progress, new challenges and emerging opportunities. Semin. Cancer Biol., 2019, 55: 37-52

[42] Wouters J et al. Robust gene expression programs underlie recurrent cell states and phenotype switching in melanoma. Nat. Cell Biol., 2020, 22: 986-998

[43] Zhang L et al. Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer. Cell, 2020, 181: 442-459 e429

[44] Kim N et al. Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. Nat. Commun., 2020, 11

[45] Wang Z et al. Glioblastoma cell differentiation trajectory predicts the immunotherapy response and overall survival of patients. Aging, 2020, 12: 18297-18321

[46] Cron KR et al. Proteasome inhibitors block DNA repair and radiosensitize non-small cell lung cancer. PLoS One, 2013, 8: e73710

[47] Delyon J, Lebbe C, Dumaz N. Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma. Curr. Opin. Oncol., 2020, 32: 79-84

[48] Oh DY, Bang YJ. HER2-targeted therapies—a role beyond breast cancer. Nat. Rev. Clin. Oncol., 2020, 17: 33-48

[49] Esteva FJ, Hubbard-Lucey VM, Tang J, Pusztai L. Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol., 2019, 20: e175-e186

[50] Quintanal-Villalonga A et al. FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy. EBioMedicine, 2020, 53: 102683

[51] Roskoski R Jr. The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders. Pharm. Res., 2018, 129: 65-83

[52] Pawade TA et al. Effect of denosumab or alendronic acid on the progression of aortic stenosis: a double-blind randomized controlled trial. Circulation, 2021, 143: 2418-2427

[53] Sherr CJ, Beach D, Shapiro GI. Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov., 2016, 6: 353-367

[54] Huang X et al. Targeting epigenetic crosstalk as a therapeutic strategy for EZH2-aberrant solid tumors. Cell, 2018, 175: 186-199.e119

[55] Prasetyanti PR, Medema JP. Intra-tumor heterogeneity from a cancer stem cell perspective. Mol. Cancer, 2017, 16

[56] da Silva-Diz V, Lorenzo-Sanz L, Bernat-Peguera A, Lopez-Cerda M, Munoz P. Cancer cell plasticity: impact on tumor progression and therapy response. Semin. Cancer Biol., 2018, 53: 48-58

[57] Maurizi G, Verma N, Gadi A, Mansukhani A, Basilico C. Sox2 is required for tumor development and cancer cell proliferation in osteosarcoma. Oncogene, 2018, 37: 4626-4632

[58] Wang T et al. The TGFbeta-miR-499a-SHKBP1 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like cells. J. Exp. Clin. Cancer Res., 2019, 38: 226

[59] Dominguez CX et al. Single-cell RNA sequencing reveals stromal evolution into LRRC15(+) myofibroblasts as a determinant of patient response to cancer immunotherapy. Cancer Discov., 2020, 10: 232-253

[60] Izar B et al. A single-cell landscape of high-grade serous ovarian cancer. Nat. Med., 2020, 26: 1271-1279

[61] Yang Z et al. Single-cell sequencing reveals variants in ARID1A, GPRC5A and MLL2 driving self-renewal of human bladder cancer stem cells. Eur. Urol., 2017, 71: 8-12

[62] van Galen P et al. Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity. Cell, 2019, 176: 1265-1281 e1224

[63] Zhou J et al. Targeting EZH2 histone methyltransferase activity alleviates experimental intestinal inflammation. Nat. Commun., 2019, 10

[64] Zhang T et al. EZH2-dependent epigenetic modulation of histone H3 lysine-27 contributes to psoriasis by promoting keratinocyte proliferation. Cell Death Dis., 2020, 11

[65] Adamik J et al. EZH2 or HDAC1 inhibition reverses multiple myeloma-induced epigenetic suppression of osteoblast differentiation. Mol. Cancer Res., 2017, 15: 405-417

[66] Zhang B, Fan DB, Liu L, Qin Y, Feng DQ. Knockdown of ZEB2-AS1 inhibits cell proliferation, invasion and induces apoptosis in osteosarcoma by combining with EZH2. Eur. Rev. Med. Pharm. Sci., 2020, 24: 6533-6539

[67] Yang L et al. FOXP4-AS1 participates in the development and progression of osteosarcoma by downregulating LATS1 via binding to LSD1 and EZH2. Biochem. Biophys. Res. Commun., 2018, 502: 493-500

[68] Sun R et al. Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential. Oncotarget, 2016, 7: 38333-38346

[69] Wen Y et al. EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells. Theranostics, 2021, 11: 1795-1813

[70] Gorodetska I, Lukiyanchuk V, Peitzsch C, Kozeretska I, Dubrovska A. BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype. Int. J. Cancer, 2019, 145: 2974-2985

[71] Italiano A et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol., 2018, 19: 649-659

[72] Yap TA et al. Phase I study of the novel enhancer of zeste homolog 2 (EZH2) inhibitor GSK2816126 in patients with advanced hematologic and solid tumors. Clin. Cancer Res., 2019, 25: 7331-7339

Funding

National Natural Science Foundation of China (National Science Foundation of China)(82173028)